ANIMAL TESTS SUPPORT PHARMACO-KINESIS MAGNETIC BREATHER PUMP

INGLEWOOD, CALIFORNIA, June 29, 2009 – Pharmaco-Kinesis Corporation (PKC), an advanced medical device company developing smart local drug delivery systems, today reported the positive results of animal testing that support the development of the Company's lead project, the Magnetic Breather Pump™ (MBP).

Small animal trials funded by PKC at the University of Southern California (USC) in 2008-9 have demonstrated that extended intratumoral delivery of medications using simple, implantable pump devices significantly increased survival of mice with aggressive brain tumors known as gliomas. "This study – the first in a series of animal studies we are planning – provides a very positive basis for the development of an implantable device to treat brain tumors,” said Josh Shachar, Founder, Director and Chairman of the Scientific Advisory Board of Pharmaco-Kinesis. "We expect to have the first miniaturized version of the Magnetic Breather Pump completed in early 2010 and plan to conduct additional studies – this time in large animals – during the first half of 2010."

The animal study was conducted by Thomas C. Chen, M.D., Ph.D., Director of Surgical Neuro-Oncology at USC and Chief Oncology Officer of Pharmaco-Kinesis. These results will be presented as an oral abstract at the Congress of Neurological Surgeons meeting in New Orleans in October 2009. The abstract was also the recipient of the prestigious Stryker Award in Neuro-Oncology.

Although the animal studies in mice with gliomas have demonstrated that extended local delivery of medications significantly increases survival, no implantable pumps have been developed for this purpose in humans. The MBP under development by PKC for local intratumoral drug delivery will thus be the first implantable pump for treatment of gliomas and other brain tumors and will contain many features to increase efficacy of delivery and treatment.

The MBP can potentially eliminate repeated brain surgery procedures, reduce the cost and enhance the effectiveness of tumor fighting medications while also improving patient quality of life and increasing patient survival.

The MBP development project was presented by Dr. Chen in May 2009 at the World Federation Neuro-Oncology Conference in Japan. The presentation received significant interest from many physicians and other participants at the conference.

ANIMAL STUDY RESULTS
The study at USC demonstrated the effectiveness of local delivery of chemotherapy in mice implanted with glioma cells. The mice were treated with chemotherapeutic agents, both systemically and via an implanted mini-pump. Figure 1 demonstrates the survival curves of the animals treated. Control animals treated with a saline solution alone were all dead by 30 days post implantation. Animals treated with intravenous Avastin, a drug developed by Genentech Inc., now owned by Roche Holding AG, by an additional chemotherapy agent, intraperitoneal CPT-11, and intravenous Avastin with intraperitoneal CPT-11, survived longer than control mice by approximately 10 days.. The greatest survival advantage was in mice treated through intratumoral delivery via the mini-pump with Avastin in combination with intraperitoneal CPT-11. These mice demonstrated greatly increased survival compared to mice treated through systemic delivery, with a survival time close to 60 days in the last surviving animal.

Under the leadership of Josh Shachar, the PKC R&D team is engaged in several product development programs for commercialization of novel smart local drug delivery technologies and advanced devices to measure biological responses.

For additional information, please contact:
Daniel Saks Senior
Vice President, Corporate Affairs
Pharmaco-Kinesis Corporation
(310) 734-4447